📊 NOTV Key Takeaways
Is NOTV a Good Investment? Thesis Analysis
Inotiv demonstrates severe operational distress with persistent negative profitability despite modest revenue growth of 4.5% YoY. The company is bleeding cash with negative operating and free cash flow while carrying unsustainable leverage of 3.72x debt-to-equity, leaving minimal liquidity cushion with a critical 0.30x current ratio.
Why Buy NOTV? Key Strengths
- Revenue growth of 4.5% YoY demonstrates continued customer demand in commercial research services
- Gross margin of 24.9% indicates reasonable pricing power and cost structure at the production level
- Marginal improvement in diluted EPS of 49.6% YoY suggests some operational stabilization efforts
NOTV Investment Risks to Consider
- Operating margin of -13.5% and net margin of -23.5% indicate fundamental unprofitability and value destruction at scale
- Dangerously low liquidity with current ratio of 0.30x and quick ratio of 0.22x creates imminent solvency concerns
- Extreme leverage with $405.8M long-term debt against $109M equity and negative interest coverage of -3.8x indicates inability to service debt obligations from operations
- Negative operating cash flow of -5.4M and free cash flow of -10.6M demonstrate cash burn with no organic cash generation
- ROE of -26.0% and ROA of -3.9% show shareholder capital is being destroyed
Key Metrics to Watch
- Operating cash flow trend and path to positive cash generation
- Operating margin improvement trajectory toward breakeven
- Debt reduction progress and refinancing capability
- Current ratio improvement toward 1.0x minimum threshold
NOTV Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
NOTV Profitability Ratios
NOTV vs Healthcare Sector
How Inotiv, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NOTV Overvalued or Undervalued?
Based on fundamental analysis, Inotiv, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NOTV Balance Sheet & Liquidity
NOTV 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Inotiv, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.10 indicates the company is currently unprofitable.
NOTV Growth Metrics (YoY)
NOTV Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $119.9M | -$27.6M | $-0.83 |
| Q3 2025 | $105.8M | -$14.9M | $-0.51 |
| Q2 2025 | $119.0M | -$14.9M | $-0.44 |
| Q1 2025 | $119.9M | -$15.4M | $-0.60 |
| Q3 2024 | $105.8M | $1.8M | $0.07 |
| Q2 2024 | $119.0M | -$10.0M | $-0.39 |
| Q1 2024 | $122.8M | -$15.4M | $-0.60 |
| Q3 2023 | $157.5M | $1.8M | $0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NOTV Capital Allocation
NOTV SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Inotiv, Inc. (CIK: 0000720154)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NOTV
What is the AI rating for NOTV?
Inotiv, Inc. (NOTV) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NOTV's key strengths?
Claude: Revenue growth of 4.5% YoY demonstrates continued customer demand in commercial research services. Gross margin of 24.9% indicates reasonable pricing power and cost structure at the production level.
What are the risks of investing in NOTV?
Claude: Operating margin of -13.5% and net margin of -23.5% indicate fundamental unprofitability and value destruction at scale. Dangerously low liquidity with current ratio of 0.30x and quick ratio of 0.22x creates imminent solvency concerns.
What is NOTV's revenue and growth?
Inotiv, Inc. reported revenue of $120.9M.
Does NOTV pay dividends?
Inotiv, Inc. does not currently pay dividends.
Where can I find NOTV SEC filings?
Official SEC filings for Inotiv, Inc. (CIK: 0000720154) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NOTV's EPS?
Inotiv, Inc. has a diluted EPS of $-0.83.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NOTV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Inotiv, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NOTV stock overvalued or undervalued?
Valuation metrics for NOTV: ROE of -26.0% (sector avg: 15%), net margin of -23.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NOTV stock in 2026?
Our dual AI analysis gives Inotiv, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NOTV's free cash flow?
Inotiv, Inc.'s operating cash flow is $-5.4M, with capital expenditures of $5.2M. FCF margin is -8.8%.
How does NOTV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -23.5% (avg: 12%), ROE -26.0% (avg: 15%), current ratio 0.30 (avg: 2).